Opinions expressed by Entrepreneur contributors are their own. Entrepreneurs work hard, you owe it to yourself to have a little...
year
/ Comparing Month and Year Data using Beast Modes in Domo Problem Statement: It is important to be able to compare...
MicroChannel Awarded SAP Partner of the Year for ANZ and Boyum APJ Partner of the Year MicroChannel is excited to announce...
A side hustle is not only an opportunity to earn extra money but also a key to escaping the 9-to-5...
Connect with gaming and metaverse leaders online at GamesBeat Summit: Into the Metaverse 3 this February 1-2. Register here. Elden...
Yesterday, my brother-in-martech Frans Riemersma and I gave a tour de force presentation of the current martech landscape as it...
80% of customers said they were more likely to buy from companies that offered personalized marketing experiences, and the same...
For his side hustle, this week’s guest didn’t start from scratch. Instead, he bought a business that was already profitable,...
BOSTON, April 6, 2021 /PRNewswire/ -- Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and...
In a reduction to companies across the spectrum, the authorities has extended deadline for required adoption of accounting software program...
– Upsized IPO in February 2021 raised $264.5 million in gross proceeds plus Series C raised $93.5 million for a...
NESS ZIONA, Israel--(BUSINESS WIRE)--Mar 31, 2021--BiomX Inc. (NYSE American: PHGE) (“BiomX” or the “Company”), a clinical-stage microbiome company advancing novel...
WOBURN, Mass.--(Enterprise WIRE)--Mar 29, 2021--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a medical-stage biotechnology organization concentrated on harnessing the body’s innate biology...
18 significant clinical milestones achieved since the Company’s IPO in January 2020, with multiple important data readouts for lemzoparlimab (TJC4),...
Q4 2020 Net Revenue $20.6 Million, Highest Net Revenue Quarter Since Launch of Jeuveau®Pro Forma Cash Position of $57 Million...
No safety concerns or evidence of Graft-versus-Host disease reported from first dose cohort of Phase 1 dose-escalation IMMUNICY-1 trial for...
- Advanced ALG-010133 and ALG-000184 into the clinic - both expected to generate safety and antiviral activity data in Chronic...
BOCA RATON, Fla., March 22, 2021 (GLOBE NEWSWIRE) -- Newtek Business Services Corp. (“Newtek” or the “Company”) (Nasdaq: NEWT), an...
